Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antiretroviral Therapy
Novel drug approaches minimize development of HIV-1 resistance to NNRTIs
September 9th, 2004
Novel drug approaches minimize the development of HIV-1 resistance to non-nucleoside reverse transcriptase inhibitors. According to recent research published in the International Journal of Biochemistry and Cell Biology, "Non-nucleoside reverse transcriptase inhibitors are potent, highly specific, noncompetitive inhibitors of the Human immunodeficiency virus type I (HIV-1) reverse transcriptase. "They are used commonly as part of potent antiretroviral regimens for the treatment of HIV-1 infection, either in combination with nucleoside analogs, protease inhibitors, or both." "A major limitation to the success of...
Source: Blood Weekly (2004-09-09)
|
